$Esperion Therapeutics (ESPR.US)$Esperion Therapeutics (ESPR): A High-Growth Opportunity with Potential 10x Returns Esperion Therapeutics (ESPR), currently trading under $2 per share, has been attracting considerable attention from analysts. Recently, three analysts reaffirmed strong "Buy" ratings, with price targets ranging from $5 to $16 per share. Among the nine analysts covering Esperion, seven h...
Johnson & Johnson Stock Forum
steady JNJ
Esperion Therapeutics (ESPR), currently trading under $2 per share, has been attracting considerable attention from analysts. Recently, three analysts reaffirmed strong "Buy" ratings, with price targets ranging from $5 to $16 per share. Among the nine analysts covering Esperion, seven h...
Can This New UC Treatment Method Transform Patient Care? TREMFYA Trial Reveals Compelling Results
Apart from being a holiday-shortened, we don’t have a lot of major events this week as compared to previous weeks. Maybe it’s a good time to take a step back and trade less?
$Salesforce (CRM.US)$ $CrowdStrike (CRWD.US)$ $Disney (DIS.US)$ $Bank of America (BAC.US)$ $Johnson & Johnson (JNJ.US)$ $Arm Holdings (ARM.US)$ $Advanced Micro Devices (AMD.US)$ $SPDR Gold ETF (GLD.US)$ $Coca-Cola (KO.US)$ $Taiwan Semiconductor (TSM.US)$ $KraneShares CSI China Internet ETF (KWEB.US)$ $Alibaba (BABA.US)$ $BABA-W (09988.HK)$ $Intel (INTC.US)$
No comment yet